About MiraVista Diagnostics

MiraVista Diagnostics was founded in 2002 by Lawrence Joseph Wheat, MD, a renowned infectious disease scientist and leading authority on endemic mycoses who developed the first Histoplasma antigen EIA at Indiana University Medical Center establishing the reference standard for antigen-based histoplasmosis diagnosis in the United States. Dr. Wheat built MiraVista as a family-owned organization with a singular mission: to advance diagnostic solutions that save lives. 

More than two decades later, that mission expanded into one of the most comprehensive fungal diagnostic platforms in the country. MiraVista processes more than 250,000 fungal diagnostic tests each year across three scientific disciplines: antigen detection, antibody testing, and molecular diagnostics for clinicians and laboratories managing Histoplasma, Blastomyces, Coccidioides, Aspergillus, Pneumocystis, and Cryptococcus. MiraVista developed the Blastomyces and Coccidioides antigen EIAs and remains the originating and performing laboratory for these tests, a distinction that reflects more than two decades of focused development in endemic mycoses diagnostics. 

MiraVista is not only a reference laboratory. It is a diagnostic developer. The MVDx Histoplasma Urine Antigen Lateral Flow Assay (CE marked and available in international markets) was built to bring rapid, accurate Histoplasma detection to clinical settings where laboratory-based testing is out of reach. It is a direct expression of our vision: a world where vulnerable populations have access to accurate diagnostic solutions, regardless of geography or resources. 

What sets MiraVista apart is not only what we test, but how we work. As a CAP and CLIA certified, family-owned laboratory, we operate with direct accountability to the clinicians, laboratory professionals, and patients we serve. Customers consistently describe what makes us different in the same terms: a knowledgeable person answers the phone, results arrive quickly, and when a clinical question is difficult, access to the performing laboratory is direct. Over 1,000 peer-reviewed publications reflect a scientific foundation built on rigor, transparency, and continuous innovation. 

Mission: We advance diagnostic solutions to save lives. 

Vision: We envision a world where vulnerable populations have access to accurate diagnostic solutions. 

Values: Teamwork · Ownership · Excellence